AstraZeneca ( AZN, $59.04)and Oxford publish promising data of coronavirus vaccine study
Britain's biopharmaceutical AstraZeneca plc and Oxford University published data from an early stage trial of a coronavirus vaccine study .
The two groups described humoral and cellular immune responses in human trials, with an acceptable safety profile. According to the study, there were 'potent' cellular and humoral immunogenicity in all 1,077 participants in the Phase 1/Phase II study.
“The immune responses observed following vaccination are in line with what we expect will be associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial programme to confirm this." , Andrew Pollard, chief investigator of the Oxford Vaccine Trial at Oxford University and co-author of the trial said. “We saw the strongest immune response in participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination,' he added.
The details of the study are published in the U.K. medical journal The Lancet.
According to Tickeron,
AZN's in Uptrend: Moving Average Convergence Divergence (MACD) Histogram just turned positive
This is a Bullish indicator signaling AZN's price could rise. Traders may explore going long on the ticker or buying call options. In 29 of 46 cases where AZN's MACD histogram became positive, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Current price $58.94 is above $53.50 the highest support line found by A.I. Throughout the month of 06/16/20 - 07/17/20, the price experienced a +14% Uptrend. During the week of 07/10/20 - 07/17/20, the stock enjoyed a +14% Uptrend growth.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator exceeded the 0 level on July 09, 2020. Traders may consider buying the ticker or exploring call options. In 48 of 80 cases where the ticker's Momentum Indicator exceeded 0, its price rose further within the subsequent month. The odds of a continued Uptrend are 60%.
The price moved above its 50-day Moving Average, which indicates a change from a Downtrend to an Uptrend. In 22 of 38 similar backtested cases where AZN's price crossed above its 50-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 58%.
The 10-day Moving Average for this ticker crossed above its 50-day Moving Average on July 09, 2020, which can be construed as a buy signal, indicating that the trend is shifting higher. In 11 of 19 similar cases where AZN's 10-day Moving Average crossed above its 50-day Moving Average, the price rose further within the following month. The odds of a continued Uptrend are 58%.
The Aroon Indicator entered an Uptrend today. In 106 of 295 similar cases where AZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 36%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the ticker has entered the overbought zone. Expect a price pull-back in the near future.
The Stochastic Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 13 of 39 cases where AZN's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 33%.
Fundamental Analysis (Ratings)
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 33%. During the last month, the daily ratio of advancing to declining volumes was 1.38 to 1.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.21) is normal, around the industry mean (-2.87). P/E Ratio (117.50) is within average values for comparable stocks, (214.31). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (35.76). AZN's Dividend Yield (2.75) is considerably higher than the industry average of (0.26). P/S Ratio (5.11) is also within normal values, averaging (227.14).
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
AZN's Stochastic Oscillator ascends into overbought zone
The Stochastic Oscillator for AZN moved into overbought territory on October 18, 2024. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for AZN crossed bearishly below the 50-day moving average on September 17, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AZN entered a downward trend on October 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AZN's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on October 17, 2024. You may want to consider a long position or call options on AZN as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 02, 2024. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in of 344 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.325) is normal, around the industry mean (5.632). P/E Ratio (35.297) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.870) is also within normal values, averaging (3.004). Dividend Yield (0.022) settles around the average of (0.164) among similar stocks. P/S Ratio (4.585) is also within normal values, averaging (3.643).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor